论文部分内容阅读
目的探究联合化疗治疗胃癌的临床效果。方法 60例胃癌患者,随机分成联合化疗组(联合化疗方案:多西他赛+奥沙利铂+替吉奥)和单纯化疗组(单纯化疗方案:奥沙利铂+卡培他滨),各30例。对比两组近期疗效和不良反应情况。结果联合化疗组疾病控制率高于单纯化疗组,差异有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论对胃癌患者实施联合化疗方案可增强化疗效果,且不会增加不良反应,临床推荐使用。
Objective To explore the clinical effect of combined chemotherapy in the treatment of gastric cancer. Methods Sixty patients with gastric cancer were randomly divided into combined chemotherapy group (combination chemotherapy: docetaxel plus oxaliplatin plus tirgilib) and chemotherapy alone group (chemotherapy alone regimen: oxaliplatin plus capecitabine) 30 cases each. The two groups compared the short-term efficacy and adverse reactions. Results The rate of disease control in the combined chemotherapy group was higher than that in the chemotherapy alone group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusions The combination of chemotherapy regimen in patients with gastric cancer can enhance the efficacy of chemotherapy, and does not increase adverse reactions, the clinical recommendation.